Xstan Beta 50 Tablet ER is a combination antihypertensive medication containing Telmisartan 40 mg and Metoprolol Succinate 50 mg in an extended-release formulation. Telmisartan is an angiotensin II receptor blocker (ARB) that selectively inhibits the binding of angiotensin II to the AT1 receptor, thereby reducing vasoconstriction and aldosterone secretion, leading to decreased blood pressure. Metoprolol Succinate is a cardioselective beta-1 adrenergic receptor blocker that reduces heart rate, myocardial contractility, and cardiac output, contributing to blood pressure reduction and improved cardiac function. The extended-release formulation ensures a consistent plasma concentration, enhancing therapeutic efficacy and patient compliance. Xstan Beta 50 is indicated for the treatment of hypertension, particularly in patients who require dual blockade of the renin-angiotensin system and beta-adrenergic receptors to achieve optimal blood pressure control. It may also be beneficial in patients with concomitant ischemic heart disease or heart failure where beta-blockade is indicated. The combination therapy offers synergistic effects, improving cardiovascular outcomes and reducing the risk of stroke, myocardial infarction, and other hypertensive complications. Use of Xstan Beta 50 should be guided by clinical evaluation, and monitoring for potential adverse effects such as hypotension, bradycardia, dizziness, and electrolyte imbalances is recommended.